Company: TELO
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010298
Chunk: 75

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 1
Chunk 75
---
 will also be entitled to an amount equal to 3% of the total value of any mergers and acquisition or strategic transactions completed
by the Company.

The
Board and the Committee, each in its sole discretion, generally retain the right to amend, supplement, supersede or cancel any awards
under the EICP for any reason, and reserve the right to determine whether and when to pay out any bonus amounts pursuant to or outside
of the EICP, regardless of the achievement of the performance targets.

13

Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The
following discussion and analysis should be read in conjunction with the Condensed Financial Statements and Notes thereto included elsewhere
in this Quarterly Report. This discussion contains certain forward-looking statements that involve risks and uncertainties. The Company’s
actual results and the timing of certain events could differ materially from those discussed in these forward-looking statements as a
result of certain factors, including, but not limited to, those set forth herein and elsewhere in this Quarterly Report and in the Company’s
other filings with the SEC. See “Cautionary Note Regarding Forward Looking Statements” below.

As
used in this Management’s Discussion and Analysis of Financial Condition and Results of Operations, unless otherwise indicated,
the terms “the Company”, “we”, “us”, “our” and similar terminology refer to Telomir Pharmaceuticals,
Inc.

Background
of the Company

Telomir-1
is a novel oral small molecule designed to regulate essential metal ions—such as iron, copper, and zinc—that are associated
with oxidative stress, telomere shortening, and cellular aging. By modulating these ions, Telomir-1 is intended to support metal homeostasis,
reduce oxidative imbalance, and help preserve telomere integrity. This approach is based on emerging research indicating that metal ion
dysregulation can accelerate oxidative stress and contribute to cellular decline. Preclinical studies have shown that Telomir-1 may influence
pathways involved in telomere maintenance and cellular protection, supporting its potential as a therapeutic candidate for further development
in age-related conditions.

To
date, we have not generated any revenue nor do we expect to generate revenue unless and until we successfully complete preclinical and
clinical development of, receive regulatory approval for, and commercialize a program and we do not know when, or if at all, that will
occur. We expect our expenses to increase substantially in connection with our ongoing activities, particularly